EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Excellent efficacy and beneficial safety during observational 5-year follow-up of rapid steroid withdrawal after renal transplantation (Harmony FU study)

Julian Stumpf, Oliver Thomusch, Mirian Opgenoorth, Michael Wiesener, Andreas Pascher, Rainer Peter Woitas, Barbara Suwelack, Markus Rentsch, Oliver Witzke, Thomas Rath, Bernhard Banas, Urs Benck und 7 weitere

Nephrology Dialysis Transplantation · 20.12.2023 · 39 (1) · 141-150

DOI: 10.1093/ndt/gfad130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 30.06.2023. Verfasst von Julian Stumpf und 18 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Carl Gustav Carus at the Technische Universität Dresden, Department of Internal Medicine III, Division of Nephrology, Dresden, Ge…. Hauptthemen laut MEDLINE: Kidney Transplantation. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Harmony FU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We previously reported excellent efficacy and improved safety aspects of rapid steroid withdrawal (RSWD) in the randomized controlled 1-year “Harmony” trial with 587 predominantly deceased-donor kidney transplant recipients randomized either to basiliximab or rabbit antithymocyte globulin induction therapy and compared with standard immunosuppressive therapy consisting of basiliximab, low tacrolimus once daily, mycophenolate mofetil and corticosteroids.

Methods

The 5-year post-trial follow-up (FU) data were obtained in an observational manner at a 3- and a 5-year visit only for those Harmony patients who consented to participate and covered clinical events that occurred from the second year onwards.

Results

Biopsy-proven acute rejection and death-censored graft loss rates remained low and independent of RSWD. Rapid steroid withdrawal was an independent positive factor for patient survival (adjusted hazard ratio 0.554, 95% confidence interval 0.314–0.976; P = .041). The reduced incidence of post-transplantation diabetes mellitus in RSWD patients during the original 1-year study period was not compensated by later incidences during FU. Incidences of other important outcome parameters such as opportunistic infections, malignancies, cardiovascular morbidity/risk factors, donor-specific antibody formation or kidney function did not differ during FU period.

Conclusions

With all the limitations of a post-trial FU study, the Harmony FU data confirm excellent efficacy and beneficial safety aspects of RSWD under modern immunosuppressive therapy over the course of 5 years after kidney transplantation in an immunologically low-risk, elderly population of Caucasian kidney transplant recipients.

Trial registration

Clinical trial registration number: Investigator Initiated Trial (NCT 00724022, FU study DRKS00005786)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationAgedHumansAntibodies, MonoclonalBasiliximabFollow-Up StudiesGraft RejectionGraft SurvivalImmunosuppressive AgentsMycophenolic AcidSteroidsTacrolimus

Stichwörter der Autor:innen

Harmony studylong-term follow-upmortalityrapid steroid withdrawalrenal transplantation

Substanzen

Antibodies, MonoclonalBasiliximabImmunosuppressive AgentsMycophenolic AcidSteroidsTacrolimus

Autor:innen und Institutionen

  • University Hospital Carl Gustav Carus at the Technische Universität Dresden, Department of Internal Medicine III, Division of Nephrology, Dresden, Germany.
  • Albert-Ludwigs University Freiburg, Department of General Surgery, Freiburg, Germany.
  • University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Department Nephrology and Hypertension, Erlangen, Germany.
  • University Hospital of Münster, Westfälische Wilhelms-University Münster Department of General, Visceral and Transplant Surgery, and Charité-Universitaetsmedizin Berlin, Campus Virchow/Mitte, Department of Surgery, Berl…
  • University Hospital of Bonn, Department of Internal Medicine I, Division of Nephrology, Bonn, Germany.
  • University Hospital of Münster, Westfälische Wilhelms-University Münster, Department of Internal Medicine D, Transplantnephrology, Münster, Germany.

ORCID-Profile: Claudia Sommerer, Julia Weinmann-Menke, Christian Hugo

Förderung

  • Harmony FU

Zitieren

APA

Stumpf, J., Thomusch, O., Opgenoorth, M., Wiesener, M., Pascher, A., Woitas, R. P., Suwelack, B., Rentsch, M., Witzke, O., Rath, T., Banas, B., Benck, U., Sommerer, C., Kurschat, C., Lopau, K., Weinmann-Menke, J., Jaenigen, B., Trips, E., & Hugo, C. (2023). Excellent efficacy and beneficial safety during observational 5-year follow-up of rapid steroid withdrawal after renal transplantation (Harmony FU study). Nephrology Dialysis Transplantation, 39(1), 141-150. https://doi.org/10.1093/ndt/gfad130

Vancouver

Stumpf J, Thomusch O, Opgenoorth M, Wiesener M, Pascher A, Woitas RP, et al. Excellent efficacy and beneficial safety during observational 5-year follow-up of rapid steroid withdrawal after renal transplantation (Harmony FU study). Nephrology Dialysis Transplantation. 2023;39(1):141-150. doi:10.1093/ndt/gfad130

BibTeX
@article{Stumpf2023,
  author = {Stumpf, Julian and Thomusch, Oliver and Opgenoorth, Mirian and Wiesener, Michael and Pascher, Andreas and Woitas, Rainer Peter and Suwelack, Barbara and Rentsch, Markus and Witzke, Oliver and Rath, Thomas and Banas, Bernhard and Benck, Urs and Sommerer, Claudia and Kurschat, Christine and Lopau, Kai and Weinmann-Menke, Julia and Jaenigen, Bernd and Trips, Evelyn and Hugo, Christian},
  title = {Excellent efficacy and beneficial safety during observational 5-year follow-up of rapid steroid withdrawal after renal transplantation (Harmony FU study)},
  journal = {Nephrology Dialysis Transplantation},
  year = {2023},
  volume = {39},
  number = {1},
  pages = {141--150},
  doi = {10.1093/ndt/gfad130}
}
Kostenlos starten →